Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

Abstract

Although approximately 95% of patients with polycythemia vera (PV) harbor the V617F mutation in JAK2 exon 14, several mutations in exon 12 have been described in the remaining patients. We conducted a European collaborative study to define the molecular and clinical features of patients harboring these mutations. Overall, 106 PVs were recruited and 17… (More)
DOI: 10.1182/blood-2010-11-316810

Topics

2 Figures and Tables